首页> 外文OA文献 >Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis

【2h】

Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis

机译：Inotuzumab ozogamicin与低强度化疗（mini-hcvd）组合，有或没有Blinatumomab与标准密集化疗（HCVAD）为老年人染色体阴性急性急性淋巴细胞白血病的前线治疗：倾向分数分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Elias J. Jabbour; Koji Sasaki; Farhad Ravandi; Nicholas J. Short; Guillermo Garcia‐Manero; Naval Daver; Tapan Kadia; Marina Konopleva; Nitin Jain; Jorge Cortes; Ghayas C. Issa; Jovitta Jacob; Monica Kwari; Philip Thompson; Rebecca Garris; Naveen Pemmaraju; Musa Yilmaz; Susan M. O’Brien; Hagop M. Kantarjian;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis [J] . Jabbour Elias J., Sasaki Koji, Ravandi Farhad, Cancer: A Journal of the American Cancer Society . 2019,第15期

机译：Inotuzumab ozogamicin与低强度化疗（mini-hcvd）组合，有或没有Blinatumomab与标准密集化疗（HCVAD）作为老年人染色体阴性急性急性淋巴细胞白血病的前线治疗：倾向评分分析
2. Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) Vs. Standard Intensive Chemotherapy (hyper-CVAD) As Frontline Therapy for Older Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Propensity Score Analysis [J] . Sasaki Koji, Kantarjian Hagop M., Short Nicholas J., Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：Inotuzumab ozogamicin与低强度化疗（迷你超级CVD）相结合。标准密集化疗（超CVAD）作为费城染色体阴性急性淋巴细胞白血病（ALL）的老年患者的前线治疗：倾向分数分析
3. Inotuzumab Ozogamicin Combined with Low-Intensity, with or without Blinatumomab vs. Intensive Therapy for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity Score Analysis [J] . Sasaki Koji, Kantarjian Hagop, Richard-Carpentier Guillaume, Clinical lymphoma, myeloma & leukemia . 2019,第Suppla1期

机译：Inotuzumab ozogamicin结合低强度，有或没有Blinatumomab与年龄患者对新诊断的费城染色体阴性急性淋巴细胞白血病的强化治疗，倾向评分分析
4. Chemoimmunotherapy with Inotuzumab Ozogamicin Combined with Mini-hyper-CVD with or without Blinatumomab Is Highly Effective in Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage [O] . Elias Jabbour, Koji Sasaki, Farhad Ravandi, -1

机译：含或不含Blinatumomab的Inotuzumab Ozogamicin联合微型超CVD的化学免疫疗法在首次抢救费城染色体阴性急性淋巴细胞白血病患者中非常有效
5. Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage [O] . Elias Jabbour, Koji Sasaki, Farhad Ravandi, 2018

机译：与inotuzumab ozogamicin的化疗疗法联合迷你超级CVD，有或没有Blinatumomab，对Filladelphia染色体阴性急性淋巴细胞白血病的患者非常有效

Inotuzumab ozogamicin in combination with low‐intensity chemotherapy (mini‐HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome‐negative acute lymphoblastic leukemia: A propensity score analysis

著录项

引文网络

相似文献

相关主题

期刊订阅